Unity Biotechnology Investor Relations Material
Latest events
Ophthalmology Day 2024
Unity Biotechnology
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Unity Biotechnology Inc
Access all reports
Unity Biotechnology, Inc., a biotechnology company, focuses on developing therapeutics designed to slow, halt, or reverse diseases associated with aging. The company's research primarily targets cellular senescence and age-related biology, with an emphasis on ophthalmologic and neurologic diseases. Unity Biotechnology's product pipeline includes UBX1325, currently in clinical trials for treating age-related eye diseases such as diabetic macular edema and age-related macular degeneration. It is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for Unity Biotechnology Inc
Ophthalmology Day 2024
Unity Biotechnology Inc
Corporate Presentation
Unity Biotechnology Inc
Latest articles
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
UBX
Country
🇺🇸 United States